section name header

Table 34.4

Pneumocystis Jirovecii Pneumonia (PCP): Diagnosis and Management

ElementComment
Patients at risk

Newly diagnosed HIV infection with advanced disease (CD4 count <200)

Patients with previous PCP or CD4 count <200 who are not taking prophylaxis

Clinical features

Subacute onset

Fever (90%)

Cough (95%), usually non-productive Progressive breathlessness (95%) Tachypnoea (60%)

Chest examination normal in 50%

Chest X-ray features

Initially normal in up to 25%

Commonest abnormalities are diffuse bilateral interstitial or alveolar shadowing

Lobar consolidation rare. Pleural effusion rare. Pneumothorax may occur

Induced sputum

Staining of induced sputum for P. jirovecii trophic forms and cysts

Specificity 100%, sensitivity 50–90%

PCR Sensitivity 98%, specificity 80–98%

Bronchoscopy with bronchoalveolar lavage

Indicated if PCP is suspected but induced sputum is non-diagnostic or cannot be done

Specificity 100%, sensitivity 80–90%

Antimicrobial therapy

First choice: co-trimoxazole PO or IV for 21 days. Causes haemolysis in glucose-6-phosphate dehydrogenase-deficient patients (African/Mediterranean). Other side effects include nausea, vomiting, fever, rash, marrow suppression and raised transaminases.

Alternative regimens: primaquine + clindamycin; atovaquone; pentamidine

Adjuvant steroid therapy

Start immediately if severe PCP (breathless at rest; PaO2 breathing air <8 kPa; extensive interstitial shadowing on chest X-ray)

Give prednisolone 40 mg twice daily PO for 5 days, followed by prednisolone 40 mg daily PO for 5 days, then prednisolone 20 mg daily PO for 11 days